You are here

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

sandy craine's picture
Submitted by sandy craine on Wed, 11/11/2015 - 11:40am

Jun Imagawa, MD, Hideo Tanaka, MD, Masaya Okada, MD, Hirohisa Nakamae, MD, Prof Masayuki Hino, MD, Kazunori Murai, MD, Prof